Abstract: The subject matter disclosed herein is directed to novel She inhibitors of Formula (II). These compounds are useful for treating impaired insulin sensitivity, glucose tolerance, obesity, diabetes, metabolic syndrome, NAFLD, NASH, PSC, PBC, or other metabolic syndrome component conditions.

Abstract: The subject matter disclosed herein is directed to novel She inhibitors of Formula (II). These compounds are useful for treating impaired insulin sensitivity, glucose tolerance, obesity, diabetes, metabolic syndrome, NAFLD, NASH, PSC, PBC, or other metabolic syndrome component conditions.

Abstract: The present invention provides pharmaceutical compounds and methods for preventing, ameliorating, or treating a mitochondrial disease by administering such compounds to a subject in need thereof. In some cases, the subject suffers from a mitochondrial disease or is predisposed to having a mitochondrial disease. The mitochondrial disease includes those associated with impairments to mitochondrial oxidative phosphorylation that can lead to vision loss or blindness.

Abstract: The present invention provides methods for preventing or treating a fibrotic disease in a subject. In some embodiments, the fibrotic disease is fatty liver disease, non-alcoholic fatty liver disease, or non-alcoholic steatohepatitis. In particular aspects, the methods comprise administering an inhibitor of Shc gene expression to achieve genetic suppression of Shc activity in the subject. In other aspects, the methods comprise administering a peptide, peptoid, or peptide-peptoid hybrid inhibitor of Shc to achieve pharmacological suppression of Shc protein activity in the subject.

Abstract: The present invention provides methods for preventing or treating a fibrotic disease in a subject. In some embodiments, the fibrotic disease is fatty liver disease, non-alcoholic fatty liver disease, or non-alcoholic steatohepatitis. In particular aspects, the methods comprise administering a small molecule inhibitor of Shc to achieve pharmacological suppression of Shc protein activity in the subject.

Abstract: This invention provides methods of treatment diabetes and related conditions using idebenone and analogs thereof compounds 10, 11, 12 and DF-1176-178.

Abstract: Provided are methods of treating muscle and liver disorders, and for increasing mitochondrial mass and/or functionality in a mammalian myocyte and/or hepatocyte.

Abstract: The present invention provides pharmaceutical compounds and methods for preventing, ameliorating, or treating a mitochondrial disease by administering such compounds to a subject in need thereof. In some cases, the subject suffers from a mitochondrial disease or is predisposed to having a mitochondrial disease. The mitochondrial disease includes those associated with impairments to mitochondrial oxidative phosphorylation that can lead to vision loss or blindness.

Abstract: This invention provides methods of identifying agents useful to prevent, ameliorate or treat one or more symptoms of Friedreich's ataxia or other neurodegenerative disease, and methods of employing the identified agents to prevent, reduce, delay or inhibit one or more symptoms of Friedreich's ataxia or other neurodegenerative disease.

Abstract: This invention provides methods of treatment diabetes and related conditions using idebenone and analogs thereof compounds 10, 11, 12 and DF-1176-178.

Abstract: This invention provides methods of identifying agents useful to prevent, ameliorate or treat one or more symptoms of impaired insulin sensitivity, glucose tolerance, obesity, diabetes, aging, metabolic syndrome, or other metabolic syndrome component diseases, and methods of employing the identified agents to prevent, reduce, delay or inhibit one or more symptoms of impaired insulin sensitivity, glucose tolerance, obesity, diabetes, aging, metabolic syndrome, or other metabolic syndrome component diseases.

Abstract: This invention provides methods of identifying agents useful to prevent, ameliorate or treat one or more symptoms of impaired insulin sensitivity, glucose tolerance, obesity, diabetes, aging, metabolic syndrome, or other metabolic syndrome component diseases, and methods of employing the identified agents to prevent, reduce, delay or inhibit one or more symptoms of impaired insulin sensitivity, glucose tolerance, obesity, diabetes, aging, metabolic syndrome, or other metabolic syndrome component diseases.

Abstract: This invention provides methods of identifying agents useful to prevent, ameliorate or treat one or more symptoms of Friedreich's ataxia or other neurodegenerative disease, and methods of employing the identified agents to prevent, reduce, delay or inhibit one or more systems of Friedreich's ataxia or other neurodegenerative disease.